Spire Wealth Management Has $393,000 Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Spire Wealth Management lowered its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 64.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,334 shares of the biotechnology company’s stock after selling 2,383 shares during the quarter. Spire Wealth Management’s holdings in Axon Enterprise were worth $393,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. ING Groep NV grew its position in Axon Enterprise by 9.3% in the 4th quarter. ING Groep NV now owns 9,643 shares of the biotechnology company’s stock valued at $2,491,000 after purchasing an additional 821 shares during the period. Avantax Advisory Services Inc. grew its position in Axon Enterprise by 0.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after purchasing an additional 40 shares during the period. GSA Capital Partners LLP bought a new position in Axon Enterprise during the 1st quarter valued at $931,000. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Axon Enterprise by 14.8% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock valued at $53,307,000 after acquiring an additional 22,013 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Axon Enterprise by 21.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock valued at $2,693,000 after acquiring an additional 1,634 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 80,300 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $371.78, for a total value of $29,853,934.00. Following the completion of the transaction, the chief executive officer now owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Patrick W. Smith sold 70,000 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $362.21, for a total value of $25,354,700.00. Following the sale, the chief executive officer now directly owns 2,945,366 shares of the company’s stock, valued at $1,066,841,018.86. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Patrick W. Smith sold 80,300 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the completion of the sale, the chief executive officer now directly owns 3,015,366 shares in the company, valued at $1,121,052,771.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 152,750 shares of company stock worth $56,105,818. 6.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Barclays raised their price objective on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Bank of America began coverage on Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $380.00 price objective on the stock. JMP Securities reiterated a “market outperform” rating and set a $375.00 target price on shares of Axon Enterprise in a research note on Wednesday, August 7th. Robert W. Baird lifted their target price on Axon Enterprise from $355.00 to $360.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. Finally, Jefferies Financial Group began coverage on Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $358.08.

Axon Enterprise Price Performance

AXON opened at $364.97 on Tuesday. The firm has a 50-day moving average price of $326.57 and a 200-day moving average price of $309.02. Axon Enterprise, Inc. has a twelve month low of $189.12 and a twelve month high of $378.89. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $27.58 billion, a price-to-earnings ratio of 106.72, a PEG ratio of 9.78 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. The business had revenue of $504.00 million during the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. Axon Enterprise’s revenue was up 34.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.80 EPS. Equities analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.